SCHEMBL21165830

SCHEMBL21165830

CCOC1CCN(C(=O)OC)C1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
VNN1 O95497 2/20 0.42
THRB P10828 1/20 0.41
ATM Q13315 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GAA P10253 2/20 0.40
CHRNB2 P17787 2/20 0.40
CHRNA4 P43681 2/20 0.40
CHRNB4 P30926 1/20 0.40
CHRNA3 P32297 1/20 0.40
PDE4B Q07343 4/20 0.39
PDE4A P27815 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
PIK3CD O00329 1/20 0.38
HSD11B1 P28845 1/20 0.36
TSHR P16473 1/20 0.36
BRD4 O60885 1/20 0.36
KCNK3 O14649 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12085750 0.82 VNN1 (0.41) VNN1THRBATML3MBTL1GAA
SCHEMBL21930188 0.82 VNN1 (0.41) VNN1THRBATML3MBTL1GAA
SCHEMBL12801554 0.82 VNN1 (0.41) VNN1THRBATML3MBTL1GAA
SCHEMBL21929958 0.82 VNN1 (0.41) VNN1THRBATML3MBTL1GAA
SCHEMBL13677274 0.82 PRMT5 (0.49) PIK3CD
SCHEMBL13677184 0.82 PRMT5 (0.49) PIK3CD
SCHEMBL10281445 0.82 PRMT5 (0.49) PIK3CD
SCHEMBL19686581 0.82 CHRNB2 (0.44) VNN1CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL791909 0.82 CHRNB2 (0.44) VNN1CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL26793108 0.82 CHRNB2 (0.44) VNN1CHRNB2CHRNA4CHRNB4CHRNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024050742-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING KRAS G12D VIA UBIQUITIN PROTEASOME PATHWAY NIKANG THERAPEUTICS, INC. (US) 2024-03-14 WO disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 VNN1 2434/4885THRB 1517/4885ATM 3611/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 VNN1 2434/4885THRB 1517/4885ATM 3611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.